Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


07.10.2024

2 Anticancer Res
3 BMC Urol
2 Int J Radiat Oncol Biol Phys
2 Int J Urol
1 J Clin Oncol
1 J Natl Cancer Inst
1 J Nucl Med
3 J Urol
1 Lancet Oncol
1 PLoS One
3 Prostate
2 Urol Int
5 Urology


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Anticancer Res

  1. RADES D, Cremers F, Ziemann C, Splettstosser L, et al
    Changes in Bladder Volume During Radiotherapy for Prostate Cancer.
    Anticancer Res. 2024;44:4457-4463.
    PubMed         Abstract available

  2. POULSEN TS, Lorup AN, Kongsted P, Eefsen RL, et al
    TMPRSS2:ERG Gene Fusion Might Predict Resistance to PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2024;44:4203-4211.
    PubMed         Abstract available


    BMC Urol

  3. PERRY AG, Kahn A, Mercuri J, Rini K, et al
    Preclinical and clinical evidence for using perinatal tissue allografts in nerve sparing robot assisted radical prostatectomy to hasten recovery of functional outcomes: a literature review.
    BMC Urol. 2024;24:208.
    PubMed         Abstract available

  4. OSHIMA M, Washino S, Yazaki K, Mayumi S, et al
    Impact of oral antithrombotic agents on urinary continence recovery following robot-assisted radical prostatectomy: a retrospective cohort study.
    BMC Urol. 2024;24:211.
    PubMed         Abstract available

  5. ZHU Z, Zhu Y, Zhou Y, Zhou P, et al
    Importance of biopsy sample length for cancer diagnosis during trans-perineal prostate biopsy.
    BMC Urol. 2024;24:209.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  6. WISDOM AJ, Yeap BY, Michalski JM, Horick NK, et al
    Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy vs. IMRT for Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2024 Sep 26:S0360-3016(24)03444.
    PubMed         Abstract available

  7. MORGAN KM, Deshler LN, Tibbs MD, Qiao EM, et al
    Prostate Specific Antigen and Prostate Cancer in Gender Affirming Hormone Therapy for Transgender or Nonbinary Individuals.
    Int J Radiat Oncol Biol Phys. 2024 Sep 25:S0360-3016(24)03409.
    PubMed         Abstract available


    Int J Urol

  8. YANAI Y, Mikami S, Yasumizu Y, Takeda T, et al
    Loss of phosphatase and tensin homolog expression castration-sensitive prostate cancer predicts outcomes in men after prostatectomy.
    Int J Urol. 2024 Oct 1. doi: 10.1111/iju.15592.
    PubMed         Abstract available

  9. KOHADA Y, Kitano H, Tasaka R, Miyamoto S, et al
    Clinical characteristics and predictors of long-term postoperative urinary incontinence in patients treated with robot-assisted radical prostatectomy: A propensity-matched analysis.
    Int J Urol. 2024;31:1145-1152.
    PubMed         Abstract available


    J Clin Oncol

  10. BROOKS JD
    Stockholm3 in a Multiethnic Cohort: Optimizing Prostate Cancer Screening to Reduce Harm and Improve Equity.
    J Clin Oncol. 2024 Oct 3:JCO2400941. doi: 10.1200/JCO.24.00941.
    PubMed        


    J Natl Cancer Inst

  11. COOPERBERG MR, Braun AE, Berlin A, Kibel AS, et al
    When is prostate cancer really cancer?
    J Natl Cancer Inst. 2024 Oct 1:djae200. doi: 10.1093.
    PubMed         Abstract available


    J Nucl Med

  12. PISANO G, van Oosterom MN, Berrens AC, Slof LJ, et al
    Freehand SPECT Combined with 3-Dimensional Light Detection and Ranging as Alternative Means of Specimen Scanning During Prostate Cancer Surgery.
    J Nucl Med. 2024 Oct 3:jnumed.124.268256. doi: 10.2967/jnumed.124.268256.
    PubMed        


    J Urol

  13. STONE BV, Dominas CA, Bhagavatula SK, Ahn SW, et al
    Novel intraprostatic MR-guided implantation of multidrug-eluting microdevice for testing of systemic therapy agents in situ; Proof of concept in intermediate- and high-risk prostate cancer.
    J Urol. 2024 Sep 30:101097JU0000000000004269. doi: 10.1097/JU.0000000000004269.
    PubMed         Abstract available

  14. BHANJI Y, Mamawala MK, Fletcher SA, Landis P, et al
    Is Confirmatory Biopsy Still Necessary for Active Surveillance of Men With Grade Group 1 Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging?
    J Urol. 2024 Oct 2:101097JU0000000000004268. doi: 10.1097/JU.0000000000004268.
    PubMed         Abstract available

  15. FLORES JM, Vertosick EA, Salter CA, Benfante N, et al
    Testosterone Therapy in Men After Radical Prostatectomy for Organ-Confined, Low-Intermediate Prostate Cancer.
    J Urol. 2024 Sep 30:101097JU0000000000004267. doi: 10.1097/JU.0000000000004267.
    PubMed         Abstract available


    Lancet Oncol

  16. JIA AY, Spratt DE
    A step closer to the use of [(177)Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer.
    Lancet Oncol. 2024;25:1246-1247.
    PubMed        


    PLoS One

  17. O'DONNELL A, Cronin M, Moghaddam S, Wolsztynski E, et al
    Pre-operative prediction of BCR-free survival with mRNA variables in prostate cancer.
    PLoS One. 2024;19:e0311162.
    PubMed         Abstract available


    Prostate

  18. DINCKAL M, Ergun KE, Kalemci MS, Guler E, et al
    Head-to-head comparison of GA-68 PSMA PET/CT and multiparametric MRI findings with postoperative results in preoperative locoregional staging and localization of prostate cancer.
    Prostate. 2024 Sep 30. doi: 10.1002/pros.24799.
    PubMed         Abstract available

  19. NARITA S, Yanagisawa T, Hatakeyama S, Hata K, et al
    Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy.
    Prostate. 2024 Sep 30. doi: 10.1002/pros.24802.
    PubMed         Abstract available

  20. YAZGAN SC, Yekeduz E, Araz M, Bolek H, et al
    The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 ((177)Lu)-PSMA-617.
    Prostate. 2024 Sep 29. doi: 10.1002/pros.24804.
    PubMed         Abstract available


    Urol Int

  21. OPPOLZER IA, Schnabel MJ, Hammer S, Zilles H, et al
    Impact of SARS-CoV-2-Pandemic on diagnosis of prostate cancer.
    Urol Int. 2024 Oct 3:1-15. doi: 10.1159/000541753.
    PubMed         Abstract available

  22. BULBUL O, Nak D, Goksel S
    Prediction of lesion-based treatment response after two cycles of Lu-177 PSMA treatment in metastatic castration-resistant prostate cancer using machine learning.
    Urol Int. 2024 Sep 30:1-12. doi: 10.1159/000541628.
    PubMed         Abstract available


    Urology

  23. BOWLING GC, Albright JA, Maloney TJ, Chesnut GT, et al
    Reply to Editorial Comment on "Poor Bone Mineral Density is Associated With Increased Risk of Urological Metastases".
    Urology. 2024;192:98-99.
    PubMed        

  24. SINGLA N
    Editorial Comment on "Poor Bone Mineral Density is Associated With Increased Risk of Urological Bone Metastases".
    Urology. 2024;192:97-98.
    PubMed        

  25. SOPUTRO NA, Olivares R
    Editorial Comment on "Impact of Preoperative LUTS on Health-related Quality of Life Following Radical Prostatectomy: A Propensity Score Matched Longitudinal Study".
    Urology. 2024;192:59-60.
    PubMed        

  26. BOWLING GC, Alex Albright J, Maloney TJ, Quinn MS, et al
    Poor Bone Mineral Density Is Associated With Increased Risk of Urological Bone Metastases.
    Urology. 2024;192:88-96.
    PubMed         Abstract available

  27. WESTHOFEN T, Feyerabend E, Buchner A, Schlenker B, et al
    Impact of Preoperative LUTS on Health-related Quality of Life Following Radical Prostatectomy: A Propensity Score Matched Longitudinal Study.
    Urology. 2024;192:52-58.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.